{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-072286","form_type":"8-K","ticker":null,"cik":"0001508381","company_name":"Bionik Laboratories Corp.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.153691+00:00","generated_at":"2026-06-13T22:35:09.316905+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bionik explores 'going dark', cost-cutting; launches up to $2M debt offering","bullets":["Private offering of convertible notes up to $2M; initial $220k from Chairman affiliate Andre-Jacques Auberton-Herve.","Directors convert $108,333 each in accrued fees into promissory notes with 1% monthly interest.","Exploring cost-cutting including possible 'going dark' by suspending SEC filings, reducing board, headcount, and facility space.","Outstanding notes converted into 4,083,544 shares; 3.1M shares to director affiliate.","Company considers sale or restructuring; net proceeds from offering for working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-072286","json":"https://secwatch.observer/filing/0001104659-23-072286.json","markdown":"https://secwatch.observer/filing/0001104659-23-072286.md","text":"https://secwatch.observer/filing/0001104659-23-072286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1508381/000110465923072286/0001104659-23-072286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1508381/000110465923072286/tm2318913d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:35:09.316905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d21b2fbcc1ad033b5e3f488f0c6da1a24c9e33a","claim":"Bionik Laboratories Corp. incurred convertible notes of $108,333 of accrued director fees due and owing to each of them with Audrey Frederique Thevenon, and on June 16, 2023, Joseph Martin, each a director of the Company at 1% per month maturing the earlier of (a) the 10-year anniversary of the issue date, (b) such date that the Company generates at least $10 million in annual revenues and (c) the consu.","evidence_excerpt":"On June 14, 2023, Audrey Frederique Thevenon, and on June 16, 2023, Joseph Martin, each a director of the Company, agreed to convert $108,333 of accrued director fees due and owing to each of them (the “Accrued Director Fees”), into a promissory note (each, “Director Note”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1508381/000110465923072286/0001104659-23-072286-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$108,333 of accrued director fees due and owing to each of them"},{"label":"Counterparty","value":"Audrey Frederique Thevenon, and on June 16, 2023, Joseph Martin, each a director of the Company"},{"label":"Rate","value":"1% per month"},{"label":"Maturity","value":"the earlier of (a) the 10-year anniversary of the issue date, (b) such date that the Company generates at least $10 million in annual revenues and (c) the consu"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"effddeba3bcf02977d3dd1550929401a116d798b","claim":"Bionik Laboratories Corp. incurred convertible notes of up to $2,000,000, with an initial subscription of $220,000 with an affiliate of the Company’s Chairman, Andre-Jacques Auberton-Herve at 1% per month maturing June 1, 2024.","evidence_excerpt":"On June 13, 2023, Bionik Laboratories Corp. (the “Company”) launched a new private offering (the “Private Offering”) of its convertible promissory notes (the “Notes”) of up to $2,000,000, with an initial subscription of $220,000 from an affiliate of the Company’s Chairman, Andre-Jacques Auberton-Herve (the “Holder”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1508381/000110465923072286/0001104659-23-072286-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"up to $2,000,000, with an initial subscription of $220,000"},{"label":"Counterparty","value":"an affiliate of the Company’s Chairman, Andre-Jacques Auberton-Herve"},{"label":"Rate","value":"1% per month"},{"label":"Maturity","value":"June 1, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}